2020 Neuromyelitis Optica (Devic's Syndrome) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Neuromyelitis Optica (Devic's Syndrome) pipeline report presents a comprehensive overview of the research and development of Neuromyelitis Optica (Devic's Syndrome) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Three drugs in Research phase, Ten drugs in pre-clinical phase, six drugs in Phase 1, one drug in Phase 2, four drugs in Phase 3 and one drug pre-registration
As of February 2020, the Neuromyelitis Optica (Devic's Syndrome) pipeline remains robust with 26 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Neuromyelitis Optica (Devic's Syndrome) treatment. Diverse types of targeted therapies are being explored through clinical trials including Anti-FcRn fully human monoclonal antibody; B lymphocyte stimulator inhibitor; CD19 antigen inhibitors; CD20 antigen inhibitors; Complement C3 inhibitor; Complement C5 inhibitors; Cytotoxic T lymphocyte stimulants; Estrogen receptor agonists; Interleukin 6 receptor antagonists; Monoacylglycerol lipase inhibitors; NF-kappa B inhibitors; RGMA protein inhibitors; Serum-glucocorticoid regulated kinase stimulants; STAT3 transcription factor inhibitors; Steroid receptor agonists; T lymphocyte stimulants; Th17 cell modulators; RORgt antagonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Neuromyelitis Optica (Devic's Syndrome) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Neuromyelitis Optica (Devic's Syndrome) pipeline drugs profiled in the report include- ACT001, AT-1511, eculizumab, ravulizumab, rituximab, BN201, BAT4406F, ARN-6039 (BOS-172767), cladribine, SA237 (satralizumab), CNP-Aquaporin 4, NDC-1308, ENX-201 (glutathione PEGylated liposomal methylprednisolone/2B3-201), olamkicept (FE-301), ABX-1431, batoclimab, Synthetic Peptide for Neuromyelitis Optica, IMS001, IMS002, ublituximab, MT-3921, Complement C3-C5 inhibitors for Neuromyelitis Optica, ORNx-KI, TOL-3052, inebilizumab, telitacicept
As of February 2020, the Neuromyelitis Optica (Devic's Syndrome) pipeline remains robust with 26 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Neuromyelitis Optica (Devic's Syndrome) treatment. Diverse types of targeted therapies are being explored through clinical trials including Anti-FcRn fully human monoclonal antibody; B lymphocyte stimulator inhibitor; CD19 antigen inhibitors; CD20 antigen inhibitors; Complement C3 inhibitor; Complement C5 inhibitors; Cytotoxic T lymphocyte stimulants; Estrogen receptor agonists; Interleukin 6 receptor antagonists; Monoacylglycerol lipase inhibitors; NF-kappa B inhibitors; RGMA protein inhibitors; Serum-glucocorticoid regulated kinase stimulants; STAT3 transcription factor inhibitors; Steroid receptor agonists; T lymphocyte stimulants; Th17 cell modulators; RORgt antagonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Neuromyelitis Optica (Devic's Syndrome) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Neuromyelitis Optica (Devic's Syndrome) development
- Neuromyelitis Optica (Devic's Syndrome) pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Neuromyelitis Optica (Devic's Syndrome) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Neuromyelitis Optica (Devic's Syndrome) pipeline candidates included
- Business overview and snapshot of all companies involved in Neuromyelitis Optica (Devic's Syndrome) pipeline are included
- Latest market and pipeline developments are provided in the report
Neuromyelitis Optica (Devic's Syndrome) pipeline drugs profiled in the report include- ACT001, AT-1511, eculizumab, ravulizumab, rituximab, BN201, BAT4406F, ARN-6039 (BOS-172767), cladribine, SA237 (satralizumab), CNP-Aquaporin 4, NDC-1308, ENX-201 (glutathione PEGylated liposomal methylprednisolone/2B3-201), olamkicept (FE-301), ABX-1431, batoclimab, Synthetic Peptide for Neuromyelitis Optica, IMS001, IMS002, ublituximab, MT-3921, Complement C3-C5 inhibitors for Neuromyelitis Optica, ORNx-KI, TOL-3052, inebilizumab, telitacicept
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Neuromyelitis Optica (Devic's Syndrome) Condition
2.3 Neuromyelitis Optica (Devic's Syndrome) Pipeline Snapshot, 2020
2.4 Companies investing in Neuromyelitis Optica (Devic's Syndrome) pipeline therapeutics
2.5 Phase wise Neuromyelitis Optica (Devic's Syndrome) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Neuromyelitis Optica (Devic's Syndrome) Pipeline Products
2.7 Route of Administration of Neuromyelitis Optica (Devic's Syndrome) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Accendatech Au Pty Ltd Overview, Contacts and ASD Pipeline Drugs
3.2 Ahead Therapeutics SL Overview, Contacts and ASD Pipeline Drugs
3.3 Alexion Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Biogen Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Bionure Farma SL Overview, Contacts and ASD Pipeline Drugs
3.6 Bio-Thera Solutions Ltd Overview, Contacts and ASD Pipeline Drugs
3.7 Boston Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Chord Therapeutics Sarl Overview, Contacts and ASD Pipeline Drugs
3.9 Chugai Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.10 Cour Pharmaceuticals Development Co Inc Overview, Contacts and ASD Pipeline Drugs
3.11 Endece LLC Overview, Contacts and ASD Pipeline Drugs
3.12 EnhanX Biopharm Inc Overview, Contacts and ASD Pipeline Drugs
3.13 Ferring International Center SA Overview, Contacts and ASD Pipeline Drugs
3.14 H. Lundbeck AS Overview, Contacts and ASD Pipeline Drugs
3.15 HanAll Biopharma Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.16 ImCyse SA Overview, Contacts and ASD Pipeline Drugs
3.17 Imstem Biotechnology Inc Overview, Contacts and ASD Pipeline Drugs
3.18 Mitsubishi Tanabe Pharma Corp Overview, Contacts and ASD Pipeline Drugs
3.19 NovelMed Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.20 Orion BioScience Inc Overview, Contacts and ASD Pipeline Drugs
3.21 TG Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.22 Tolerion Inc Overview, Contacts and ASD Pipeline Drugs
3.23 Viela Bio Inc Overview, Contacts and ASD Pipeline Drugs
3.24 Yantai RC-Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 ACT001 Drug Details
4.1.1 ACT001 Current Status
4.1.2 ACT001 Drug Overview
4.1.3 ACT001 Mechanism of Action
4.1.4 ACT001 Licensing/Collaboration Companies
4.1.5 ACT001 Clinical Trials
4.2 AT-1511 Drug Details
4.2.1 AT-1511 Current Status
4.2.2 AT-1511 Drug Overview
4.2.3 AT-1511 Mechanism of Action
4.2.4 AT-1511 Licensing/Collaboration Companies
4.2.5 AT-1511 Clinical Trials
4.3 eculizumab Drug Details
4.3.1 eculizumab Current Status
4.3.2 eculizumab Drug Overview
4.3.3 eculizumab Mechanism of Action
4.3.4 eculizumab Licensing/Collaboration Companies
4.3.5 eculizumab Clinical Trials
4.4 ravulizumab Drug Details
4.4.1 ravulizumab Current Status
4.4.2 ravulizumab Drug Overview
4.4.3 ravulizumab Mechanism of Action
4.4.4 ravulizumab Licensing/Collaboration Companies
4.4.5 ravulizumab Clinical Trials
4.5 rituximab Drug Details
4.5.1 rituximab Current Status
4.5.2 rituximab Drug Overview
4.5.3 rituximab Mechanism of Action
4.5.4 rituximab Licensing/Collaboration Companies
4.5.5 rituximab Clinical Trials
4.6 BN201 Drug Details
4.6.1 BN201 Current Status
4.6.2 BN201 Drug Overview
4.6.3 BN201 Mechanism of Action
4.6.4 BN201 Licensing/Collaboration Companies
4.6.5 BN201 Clinical Trials
4.7 BAT4406F Drug Details
4.7.1 BAT4406F Current Status
4.7.2 BAT4406F Drug Overview
4.7.3 BAT4406F Mechanism of Action
4.7.4 BAT4406F Licensing/Collaboration Companies
4.7.5 BAT4406F Clinical Trials
4.8 ARN-6039 (BOS-172767) Drug Details
4.8.1 ARN-6039 (BOS-172767) Current Status
4.8.2 ARN-6039 (BOS-172767) Drug Overview
4.8.3 ARN-6039 (BOS-172767) Mechanism of Action
4.8.4 ARN-6039 (BOS-172767) Licensing/Collaboration Companies
4.8.5 ARN-6039 (BOS-172767) Clinical Trials
4.9 cladribine Drug Details
4.9.1 cladribine Current Status
4.9.2 cladribine Drug Overview
4.9.3 cladribine Mechanism of Action
4.9.4 cladribine Licensing/Collaboration Companies
4.9.5 cladribine Clinical Trials
4.10 SA237 (satralizumab) Drug Details
4.10.1 SA237 (satralizumab) Current Status
4.10.2 SA237 (satralizumab) Drug Overview
4.10.3 SA237 (satralizumab) Mechanism of Action
4.10.4 SA237 (satralizumab) Licensing/Collaboration Companies
4.10.5 SA237 (satralizumab) Clinical Trials
4.11 CNP-Aquaporin 4 Drug Details
4.11.1 CNP-Aquaporin 4 Current Status
4.11.2 CNP-Aquaporin 4 Drug Overview
4.11.3 CNP-Aquaporin 4 Mechanism of Action
4.11.4 CNP-Aquaporin 4 Licensing/Collaboration Companies
4.11.5 CNP-Aquaporin 4 Clinical Trials
4.12 NDC-1308 Drug Details
4.12.1 NDC-1308 Current Status
4.12.2 NDC-1308 Drug Overview
4.12.3 NDC-1308 Mechanism of Action
4.12.4 NDC-1308 Licensing/Collaboration Companies
4.12.5 NDC-1308 Clinical Trials
4.13 ENX-201 (glutathione PEGylated liposomal methylprednisolone/2B3-201) Drug Details
4.13.1 ENX-201 (glutathione PEGylated liposomal methylprednisolone/2B3-201) Current Status
4.13.2 ENX-201 (glutathione PEGylated liposomal methylprednisolone/2B3-201) Drug Overview
4.13.3 ENX-201 (glutathione PEGylated liposomal methylprednisolone/2B3-201) Mechanism of Action
4.13.4 ENX-201 (glutathione PEGylated liposomal methylprednisolone/2B3-201) Licensing/Collaboration Companies
4.13.5 ENX-201 (glutathione PEGylated liposomal methylprednisolone/2B3-201) Clinical Trials
4.14 olamkicept (FE-301) Drug Details
4.14.1 olamkicept (FE-301) Current Status
4.14.2 olamkicept (FE-301) Drug Overview
4.14.3 olamkicept (FE-301) Mechanism of Action
4.14.4 olamkicept (FE-301) Licensing/Collaboration Companies
4.14.5 olamkicept (FE-301) Clinical Trials
4.15 ABX-1431 Drug Details
4.15.1 ABX-1431 Current Status
4.15.2 ABX-1431 Drug Overview
4.15.3 ABX-1431 Mechanism of Action
4.15.4 ABX-1431 Licensing/Collaboration Companies
4.15.5 ABX-1431 Clinical Trials
4.16 batoclimab Drug Details
4.16.1 batoclimab Current Status
4.16.2 batoclimab Drug Overview
4.16.3 batoclimab Mechanism of Action
4.16.4 batoclimab Licensing/Collaboration Companies
4.16.5 batoclimab Clinical Trials
4.17 Synthetic Peptide for Neuromyelitis Optica Drug Details
4.17.1 Synthetic Peptide for Neuromyelitis Optica Current Status
4.17.2 Synthetic Peptide for Neuromyelitis Optica Drug Overview
4.17.3 Synthetic Peptide for Neuromyelitis Optica Mechanism of Action
4.17.4 Synthetic Peptide for Neuromyelitis Optica Licensing/Collaboration Companies
4.17.5 Synthetic Peptide for Neuromyelitis Optica Clinical Trials
4.18 IMS001 Drug Details
4.18.1 IMS001 Current Status
4.18.2 IMS001 Drug Overview
4.18.3 IMS001 Mechanism of Action
4.18.4 IMS001 Licensing/Collaboration Companies
4.18.5 IMS001 Clinical Trials
4.19 IMS002 Drug Details
4.19.1 IMS002 Current Status
4.19.2 IMS002 Drug Overview
4.19.3 IMS002 Mechanism of Action
4.19.4 IMS002 Licensing/Collaboration Companies
4.19.5 IMS002 Clinical Trials
4.20 ublituximab Drug Details
4.20.1 ublituximab Current Status
4.20.2 ublituximab Drug Overview
4.20.3 ublituximab Mechanism of Action
4.20.4 ublituximab Licensing/Collaboration Companies
4.20.5 ublituximab Clinical Trials
4.21 MT-3921 Drug Details
4.21.1 MT-3921 Current Status
4.21.2 MT-3921 Drug Overview
4.21.3 MT-3921 Mechanism of Action
4.21.4 MT-3921 Licensing/Collaboration Companies
4.21.5 MT-3921 Clinical Trials
4.22 Complement C3-C5 inhibitors for Neuromyelitis Optica Drug Details
4.22.1 Complement C3-C5 inhibitors for Neuromyelitis Optica Current Status
4.22.2 Complement C3-C5 inhibitors for Neuromyelitis Optica Drug Overview
4.22.3 Complement C3-C5 inhibitors for Neuromyelitis Optica Mechanism of Action
4.22.4 Complement C3-C5 inhibitors for Neuromyelitis Optica Licensing/Collaboration Companies
4.22.5 Complement C3-C5 inhibitors for Neuromyelitis Optica Clinical Trials
4.23 ORNx-KI Drug Details
4.23.1 ORNx-KI Current Status
4.23.2 ORNx-KI Drug Overview
4.23.3 ORNx-KI Mechanism of Action
4.23.4 ORNx-KI Licensing/Collaboration Companies
4.23.5 ORNx-KI Clinical Trials
4.24 TOL-3052 Drug Details
4.24.1 TOL-3052 Current Status
4.24.2 TOL-3052 Drug Overview
4.24.3 TOL-3052 Mechanism of Action
4.24.4 TOL-3052 Licensing/Collaboration Companies
4.24.5 TOL-3052 Clinical Trials
4.25 inebilizumab Drug Details
4.25.1 inebilizumab Current Status
4.25.2 inebilizumab Drug Overview
4.25.3 inebilizumab Mechanism of Action
4.25.4 inebilizumab Licensing/Collaboration Companies
4.25.5 inebilizumab Clinical Trials
4.26 telitacicept Drug Details
4.26.1 telitacicept Current Status
4.26.2 telitacicept Drug Overview
4.26.3 telitacicept Mechanism of Action
4.26.4 telitacicept Licensing/Collaboration Companies
4.26.5 telitacicept Clinical Trials
5. LATEST NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Neuromyelitis Optica (Devic's Syndrome) Condition
2.3 Neuromyelitis Optica (Devic's Syndrome) Pipeline Snapshot, 2020
2.4 Companies investing in Neuromyelitis Optica (Devic's Syndrome) pipeline therapeutics
2.5 Phase wise Neuromyelitis Optica (Devic's Syndrome) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Neuromyelitis Optica (Devic's Syndrome) Pipeline Products
2.7 Route of Administration of Neuromyelitis Optica (Devic's Syndrome) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Accendatech Au Pty Ltd Overview, Contacts and ASD Pipeline Drugs
3.2 Ahead Therapeutics SL Overview, Contacts and ASD Pipeline Drugs
3.3 Alexion Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Biogen Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Bionure Farma SL Overview, Contacts and ASD Pipeline Drugs
3.6 Bio-Thera Solutions Ltd Overview, Contacts and ASD Pipeline Drugs
3.7 Boston Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Chord Therapeutics Sarl Overview, Contacts and ASD Pipeline Drugs
3.9 Chugai Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.10 Cour Pharmaceuticals Development Co Inc Overview, Contacts and ASD Pipeline Drugs
3.11 Endece LLC Overview, Contacts and ASD Pipeline Drugs
3.12 EnhanX Biopharm Inc Overview, Contacts and ASD Pipeline Drugs
3.13 Ferring International Center SA Overview, Contacts and ASD Pipeline Drugs
3.14 H. Lundbeck AS Overview, Contacts and ASD Pipeline Drugs
3.15 HanAll Biopharma Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.16 ImCyse SA Overview, Contacts and ASD Pipeline Drugs
3.17 Imstem Biotechnology Inc Overview, Contacts and ASD Pipeline Drugs
3.18 Mitsubishi Tanabe Pharma Corp Overview, Contacts and ASD Pipeline Drugs
3.19 NovelMed Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.20 Orion BioScience Inc Overview, Contacts and ASD Pipeline Drugs
3.21 TG Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.22 Tolerion Inc Overview, Contacts and ASD Pipeline Drugs
3.23 Viela Bio Inc Overview, Contacts and ASD Pipeline Drugs
3.24 Yantai RC-Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 ACT001 Drug Details
4.1.1 ACT001 Current Status
4.1.2 ACT001 Drug Overview
4.1.3 ACT001 Mechanism of Action
4.1.4 ACT001 Licensing/Collaboration Companies
4.1.5 ACT001 Clinical Trials
4.2 AT-1511 Drug Details
4.2.1 AT-1511 Current Status
4.2.2 AT-1511 Drug Overview
4.2.3 AT-1511 Mechanism of Action
4.2.4 AT-1511 Licensing/Collaboration Companies
4.2.5 AT-1511 Clinical Trials
4.3 eculizumab Drug Details
4.3.1 eculizumab Current Status
4.3.2 eculizumab Drug Overview
4.3.3 eculizumab Mechanism of Action
4.3.4 eculizumab Licensing/Collaboration Companies
4.3.5 eculizumab Clinical Trials
4.4 ravulizumab Drug Details
4.4.1 ravulizumab Current Status
4.4.2 ravulizumab Drug Overview
4.4.3 ravulizumab Mechanism of Action
4.4.4 ravulizumab Licensing/Collaboration Companies
4.4.5 ravulizumab Clinical Trials
4.5 rituximab Drug Details
4.5.1 rituximab Current Status
4.5.2 rituximab Drug Overview
4.5.3 rituximab Mechanism of Action
4.5.4 rituximab Licensing/Collaboration Companies
4.5.5 rituximab Clinical Trials
4.6 BN201 Drug Details
4.6.1 BN201 Current Status
4.6.2 BN201 Drug Overview
4.6.3 BN201 Mechanism of Action
4.6.4 BN201 Licensing/Collaboration Companies
4.6.5 BN201 Clinical Trials
4.7 BAT4406F Drug Details
4.7.1 BAT4406F Current Status
4.7.2 BAT4406F Drug Overview
4.7.3 BAT4406F Mechanism of Action
4.7.4 BAT4406F Licensing/Collaboration Companies
4.7.5 BAT4406F Clinical Trials
4.8 ARN-6039 (BOS-172767) Drug Details
4.8.1 ARN-6039 (BOS-172767) Current Status
4.8.2 ARN-6039 (BOS-172767) Drug Overview
4.8.3 ARN-6039 (BOS-172767) Mechanism of Action
4.8.4 ARN-6039 (BOS-172767) Licensing/Collaboration Companies
4.8.5 ARN-6039 (BOS-172767) Clinical Trials
4.9 cladribine Drug Details
4.9.1 cladribine Current Status
4.9.2 cladribine Drug Overview
4.9.3 cladribine Mechanism of Action
4.9.4 cladribine Licensing/Collaboration Companies
4.9.5 cladribine Clinical Trials
4.10 SA237 (satralizumab) Drug Details
4.10.1 SA237 (satralizumab) Current Status
4.10.2 SA237 (satralizumab) Drug Overview
4.10.3 SA237 (satralizumab) Mechanism of Action
4.10.4 SA237 (satralizumab) Licensing/Collaboration Companies
4.10.5 SA237 (satralizumab) Clinical Trials
4.11 CNP-Aquaporin 4 Drug Details
4.11.1 CNP-Aquaporin 4 Current Status
4.11.2 CNP-Aquaporin 4 Drug Overview
4.11.3 CNP-Aquaporin 4 Mechanism of Action
4.11.4 CNP-Aquaporin 4 Licensing/Collaboration Companies
4.11.5 CNP-Aquaporin 4 Clinical Trials
4.12 NDC-1308 Drug Details
4.12.1 NDC-1308 Current Status
4.12.2 NDC-1308 Drug Overview
4.12.3 NDC-1308 Mechanism of Action
4.12.4 NDC-1308 Licensing/Collaboration Companies
4.12.5 NDC-1308 Clinical Trials
4.13 ENX-201 (glutathione PEGylated liposomal methylprednisolone/2B3-201) Drug Details
4.13.1 ENX-201 (glutathione PEGylated liposomal methylprednisolone/2B3-201) Current Status
4.13.2 ENX-201 (glutathione PEGylated liposomal methylprednisolone/2B3-201) Drug Overview
4.13.3 ENX-201 (glutathione PEGylated liposomal methylprednisolone/2B3-201) Mechanism of Action
4.13.4 ENX-201 (glutathione PEGylated liposomal methylprednisolone/2B3-201) Licensing/Collaboration Companies
4.13.5 ENX-201 (glutathione PEGylated liposomal methylprednisolone/2B3-201) Clinical Trials
4.14 olamkicept (FE-301) Drug Details
4.14.1 olamkicept (FE-301) Current Status
4.14.2 olamkicept (FE-301) Drug Overview
4.14.3 olamkicept (FE-301) Mechanism of Action
4.14.4 olamkicept (FE-301) Licensing/Collaboration Companies
4.14.5 olamkicept (FE-301) Clinical Trials
4.15 ABX-1431 Drug Details
4.15.1 ABX-1431 Current Status
4.15.2 ABX-1431 Drug Overview
4.15.3 ABX-1431 Mechanism of Action
4.15.4 ABX-1431 Licensing/Collaboration Companies
4.15.5 ABX-1431 Clinical Trials
4.16 batoclimab Drug Details
4.16.1 batoclimab Current Status
4.16.2 batoclimab Drug Overview
4.16.3 batoclimab Mechanism of Action
4.16.4 batoclimab Licensing/Collaboration Companies
4.16.5 batoclimab Clinical Trials
4.17 Synthetic Peptide for Neuromyelitis Optica Drug Details
4.17.1 Synthetic Peptide for Neuromyelitis Optica Current Status
4.17.2 Synthetic Peptide for Neuromyelitis Optica Drug Overview
4.17.3 Synthetic Peptide for Neuromyelitis Optica Mechanism of Action
4.17.4 Synthetic Peptide for Neuromyelitis Optica Licensing/Collaboration Companies
4.17.5 Synthetic Peptide for Neuromyelitis Optica Clinical Trials
4.18 IMS001 Drug Details
4.18.1 IMS001 Current Status
4.18.2 IMS001 Drug Overview
4.18.3 IMS001 Mechanism of Action
4.18.4 IMS001 Licensing/Collaboration Companies
4.18.5 IMS001 Clinical Trials
4.19 IMS002 Drug Details
4.19.1 IMS002 Current Status
4.19.2 IMS002 Drug Overview
4.19.3 IMS002 Mechanism of Action
4.19.4 IMS002 Licensing/Collaboration Companies
4.19.5 IMS002 Clinical Trials
4.20 ublituximab Drug Details
4.20.1 ublituximab Current Status
4.20.2 ublituximab Drug Overview
4.20.3 ublituximab Mechanism of Action
4.20.4 ublituximab Licensing/Collaboration Companies
4.20.5 ublituximab Clinical Trials
4.21 MT-3921 Drug Details
4.21.1 MT-3921 Current Status
4.21.2 MT-3921 Drug Overview
4.21.3 MT-3921 Mechanism of Action
4.21.4 MT-3921 Licensing/Collaboration Companies
4.21.5 MT-3921 Clinical Trials
4.22 Complement C3-C5 inhibitors for Neuromyelitis Optica Drug Details
4.22.1 Complement C3-C5 inhibitors for Neuromyelitis Optica Current Status
4.22.2 Complement C3-C5 inhibitors for Neuromyelitis Optica Drug Overview
4.22.3 Complement C3-C5 inhibitors for Neuromyelitis Optica Mechanism of Action
4.22.4 Complement C3-C5 inhibitors for Neuromyelitis Optica Licensing/Collaboration Companies
4.22.5 Complement C3-C5 inhibitors for Neuromyelitis Optica Clinical Trials
4.23 ORNx-KI Drug Details
4.23.1 ORNx-KI Current Status
4.23.2 ORNx-KI Drug Overview
4.23.3 ORNx-KI Mechanism of Action
4.23.4 ORNx-KI Licensing/Collaboration Companies
4.23.5 ORNx-KI Clinical Trials
4.24 TOL-3052 Drug Details
4.24.1 TOL-3052 Current Status
4.24.2 TOL-3052 Drug Overview
4.24.3 TOL-3052 Mechanism of Action
4.24.4 TOL-3052 Licensing/Collaboration Companies
4.24.5 TOL-3052 Clinical Trials
4.25 inebilizumab Drug Details
4.25.1 inebilizumab Current Status
4.25.2 inebilizumab Drug Overview
4.25.3 inebilizumab Mechanism of Action
4.25.4 inebilizumab Licensing/Collaboration Companies
4.25.5 inebilizumab Clinical Trials
4.26 telitacicept Drug Details
4.26.1 telitacicept Current Status
4.26.2 telitacicept Drug Overview
4.26.3 telitacicept Mechanism of Action
4.26.4 telitacicept Licensing/Collaboration Companies
4.26.5 telitacicept Clinical Trials
5. LATEST NEUROMYELITIS OPTICA (DEVIC'S SYNDROME) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
